Alastair Garfield - 14 Feb 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Scientific Officer
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield
Issuer symbol
RYTM
Transactions as of
14 Feb 2025
Net transactions value
$0
Form type
4
Filing time
19 Feb 2025, 21:44:28 UTC
Previous filing
10 Jul 2024
Next filing
03 Jul 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Award $0 +26,650 $0.000000 26,650 14 Feb 2025 Common Stock 26,650 Direct F1, F2
transaction RYTM Stock Options (Right to Buy) Award $0 +40,000 $0.000000 40,000 14 Feb 2025 Common Stock 40,000 $56.69 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.
F3 The options vest and become exercisable, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date, as to 6.25% of the total number of shares of common stock subject to the options upon the Reporting Person's completion of each successive three months of service to the Issuer after February 14, 2025, such that the option shall be fully vested and exercisable on February 14, 2029.

Remarks:

Exhibit 24 - Power of Attorney